- Home
- VWAV vs ELTX Comparison
VWAV vs ELTX Comparison
Compare VWAV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VWAV
- ELTX
- Stock Information
- Founded
- VWAV 2024
- ELTX 2011
- Country
- VWAV United States
- ELTX United States
- Employees
- VWAV N/A
- ELTX N/A
- Industry
- VWAV Computer Software: Prepackaged Software
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- VWAV Technology
- ELTX Health Care
- Exchange
- VWAV Nasdaq
- ELTX Nasdaq
- Market Cap
- VWAV 162.2M
- ELTX 158.5M
- IPO Year
- VWAV N/A
- ELTX N/A
- Fundamental
- Price
- VWAV $13.39
- ELTX $9.74
- Analyst Decision
- VWAV
- ELTX Strong Buy
- Analyst Count
- VWAV 0
- ELTX 2
- Target Price
- VWAV N/A
- ELTX $11.00
- AVG Volume (30 Days)
- VWAV 342.9K
- ELTX 89.8K
- Earning Date
- VWAV 11-26-2025
- ELTX 11-12-2025
- Dividend Yield
- VWAV N/A
- ELTX N/A
- EPS Growth
- VWAV N/A
- ELTX N/A
- EPS
- VWAV N/A
- ELTX N/A
- Revenue
- VWAV N/A
- ELTX N/A
- Revenue This Year
- VWAV N/A
- ELTX N/A
- Revenue Next Year
- VWAV N/A
- ELTX N/A
- P/E Ratio
- VWAV N/A
- ELTX N/A
- Revenue Growth
- VWAV N/A
- ELTX N/A
- 52 Week Low
- VWAV $2.06
- ELTX $4.05
- 52 Week High
- VWAV $14.05
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- VWAV N/A
- ELTX 41.51
- Support Level
- VWAV N/A
- ELTX $9.50
- Resistance Level
- VWAV N/A
- ELTX $10.12
- Average True Range (ATR)
- VWAV 0.00
- ELTX 0.52
- MACD
- VWAV 0.00
- ELTX -0.05
- Stochastic Oscillator
- VWAV 0.00
- ELTX 28.00
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.